VIVE - Viveve Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3200
-0.1300 (-8.97%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.4500
Open1.4500
Bid1.27 x 2200
Ask1.31 x 900
Day's Range1.2850 - 1.4500
52 Week Range1.2600 - 5.2500
Volume192,643
Avg. Volume277,531
Market Cap59.235M
Beta (3Y Monthly)0.26
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.17
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Viveve Announces Closing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The net proceeds to Viveve from the offering were approximately $18.8 million, after deducting underwriting discounts and commissions (but before deducting estimated offering expenses payable by the Company). Viveve intends to use the net proceeds from this offering to support the continued commercialization of its products in North America and internationally, to obtain additional regulatory clearances and to conduct the VIVEVE II Sexual Function and LIBERATE – International and LIBERATE – U.S. stress urinary incontinence (SUI) clinical trials, and for general corporate and working capital purposes.

  • GlobeNewswire9 days ago

    Viveve Announces Pricing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The gross proceeds to Viveve from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Viveve, are expected to be $20.0 million. All shares of common stock are being offered by Viveve.

  • GlobeNewswire9 days ago

    Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study

    Viveve Medical, Inc. (VIVE) (“Viveve”), a medical technology company focused on women's intimate health, today announced positive 12-month data from an investigator-initiated, single-arm, 12-month feasibility study using its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform for the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. The study was conducted by Bruce Allan, PhD, MD, FRCS(C), founder and medical director of the Allan Centre in Calgary, Alberta. “These positive results build upon the demonstrated effectiveness and durability of our single-session CMRF treatment for women experiencing SUI symptoms, as previously reported in the six-month interim data from this feasibility study, as well as the 12-month data in the separate SUI pilot study,” said Scott Durbin, chief executive officer and director of Viveve.

  • GlobeNewswire9 days ago

    Viveve Announces Proposed Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be offered by Viveve. Viveve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock in connection with the public offering.

  • GlobeNewswire17 days ago

    Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

    The live webcast of this event can be accessible through the company’s investor relations website at http://ir.viveve.com. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. In the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth following an Investigational Device Exemption (IDE) application approval from the U.S. Food and Drug Administration (FDA) in March of 2018.

  • Zacks Small Cap Research20 days ago

    VIVE: Short-Term Headwinds Result in Lowered Guidance. Clinical Progress Sets Up Several Upcoming Milestones

    Viveve (VIVE) reported Q3 2018 financial results and provided a business update. While VIVE was not one of the seven, we are not overly surprised that this has caused what appears to be an overly cautious market reaction given FDA’s language in the letter that these devices (i.e.

  • GlobeNewswire25 days ago

    New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of VIVE earnings conference call or presentation 9-Nov-18 1:00pm GMT

    Q3 2018 Viveve Medical Inc Earnings Call

  • 9 Colorado companies make Deloitte’s list of fastest-growing tech companies
    American City Business Journalslast month

    9 Colorado companies make Deloitte’s list of fastest-growing tech companies

    Of the nine Colorado companies on the list, five are software companies and two are in biotech or pharmaceuticals.

  • GlobeNewswirelast month

    Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that the company has been included in Deloitte’s 2018 Technology Fast 500, a list of the 500 fastest growing technology, media, telecommunications, life sciences, and energy technology companies in North America. “We are proud to be acknowledged as the only medical device company listed among the top ten companies named to the 2018 Technology Fast 500 list. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life.

  • GlobeNewswirelast month

    Viveve Reports Third Quarter 2018 Financial Results

    Continued commercial growth for Viveve® System including record quarter of treatment tip sales Significant advancement of clinical programs targeting new indications in.

  • GlobeNewswirelast month

    Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report financial results for the third quarter ended September 30, 2018 after the close of the U.S. financial markets on Thursday, November 8, 2018. Management will host a live conference call and webcast to discuss these results and provide an update on corporate and commercial developments on Friday, November 9, 2018 at 8:00am ET. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life.

  • Simply Wall St.2 months ago

    Does The Viveve Medical Inc (NASDAQ:VIVE) Share Price Tend To Follow The Market?

    If you’re interested in Viveve Medical Inc (NASDAQ:VIVE), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of VIVE earnings conference call or presentation 9-Aug-18 9:00pm GMT

    Q2 2018 Viveve Medical Inc Earnings Call

  • Zacks Small Cap Research4 months ago

    VIVE: Sales Force Realignment Appears To Be Paying Dividends As Q2 U.S. Systems Sales Crush Prior Record

    Viveve (VIVE) reported Q2 2018 financial results and provided a business update. While international sales faltered, falling 18% from the prior year, that overseas weakness was much more than offset by extraordinarily robust domestic sales. Strength of the U.S. business, which also saw big gains on treatment tip ASPs and resultant widening of related margins, was attributed to increased production following the sales force realignment.

  • ACCESSWIRE4 months ago

    Viveve Medical Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Viveve Medical Inc (NASDAQ: VIVE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern Time. ...

  • Zacks Small Cap Research4 months ago

    VIVE: FDA Warning Letter Should Weed-Out Imposters and Benefit VIVE

    On July 30th FDA issued a Safety Communications letter warning against the use of “Energy-Based Devices to Perform Vaginal ‘Rejuvenation’ of Vaginal Cosmetic Procedures”. The purpose of the letter is to “alert patients and health care providers that the use of energy-based devices to perform vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function may be associated with serious adverse events. FDA notes that they are aware of certain device manufacturers that may be marketing for these purposes – none of which are approved for those indications.